Results 21 to 30 of about 13,391 (192)
METTL3 Gains R/W Access to the Epitranscriptome [PDF]
Molecular Cell, 2016 Epitranscriptomic marks are dynamically placed on mRNA by "writer" or "eraser" enzymes, while "readers" modulate their function accordingly. Lin et al. (2016) now report that the N6-methyladenosine:RNA methyltransferase METTL3 is both a writer and a reader, directly enhancing mRNA translation.
Ulrike, Schumann +2 more
openaire +2 more sources
Expression and clinical significance of METTL3 in colorectal cancer
Medicine, 2023 Methyltransferase-like 3 (METTL3) belongs to the class I MTase family, and it has been proved that METTL3 is highly expressed in a variety of tumors and promotes tumor progression. Our previous studies have shown that METTL3 is highly expressed in gastric cancer tissues compared with para-cancer tissues, and its expression level is negatively ...
Hui Li, Zhilin Liu, Haitao Wang
openaire +2 more sources
Critical Roles of METTL3 in Translation Regulation of Cancer
Biomolecules, 2023 Aberrant translation, a characteristic feature of cancer, is regulated by the complex and sophisticated RNA binding proteins (RBPs) in the canonical translation machinery. N6-methyladenosine (m6A) modifications are the most abundant internal modifications in mRNAs mediated by methyltransferase-like 3 (METTL3). METTL3 is commonly aberrantly expressed in
Wangyang Meng +6 more
openaire +3 more sources
Cell Death Discovery, 2022 Osteosarcoma (OS) is a prevalent primary bone sarcoma. Methyltransferase-like 3 (METTL3) is dysregulated in human malignancies. This study explored the mechanism of METTL3 in OS cell proliferation.
Renbing Jiang +5 more
doaj +1 more source
Experimental Hematology & Oncology, 2022 Background N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function.
Yu-qing Guo +7 more
doaj +1 more source
Cell Death Discovery, 2021 Ovarian cancer is a common gynecological malignant tumor with a high mortality rate and poor prognosis. There is inadequate knowledge of the molecular mechanisms underlying ovarian cancer.
Xuehan Bi +7 more
doaj +1 more source
Cell Transplantation, 2022 Accumulating data show that N6-methyladenosine (m 6 A) methyltransferase METTL3 and long noncoding RNA MALAT1 act pivotal roles in multiple malignancies including prostate cancer (PCa). However, the role and molecular mechanism underlying METTL3-mediated
Yuanshen Mao +8 more
doaj +1 more source
Biomarker Research, 2023 Background N6-methyladenosine (m6A) methylation is the most abundant chemical posttranscriptional modification of mRNA, and it is associated with the regulation of the immune response to tumors.
Lei Zhan +10 more
doaj +1 more source
Advanced Science, EarlyView.TRMT6‐mediated m1A modification in CDK9 mRNA enhances its mRNA stability and translation efficiency, thereby increasing the protein levels of CDK9. Upregulated CDK9 promotes the progression of HCC by elevating the levels of oncogenic factors including p‐STAT3, MCL1, and BCL‐2. On the other hand, CDK9 phosphorylates TARDBP at Ser254 to activate HBV core
Rui Zhang +12 more
wiley +1 more source
M6A Methyltransferase METTL3 Modulates Traumatic Brain Injury by Targeting Ferroptosis
Frontiers in Bioscience-LandmarkBackground: Traumatic brain injury (TBI) is a disease caused by external forces that damage brain structure and function. After TBI, iron accumulation and reactive oxygen species (ROS) increase lipid peroxidation, promoting ferroptosis.
Fei Qin +5 more
doaj +1 more source